Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Bio-IT World May 9, 2003 Michael Greeley	Mechanistic Models Investors are backing predictive modeling software that could speed drug development.
Bio-IT World September 11, 2003	Show Me the Evidence ... Some emerging bio-IT services companies are beginning to attract venture capital.
Pharmaceutical Executive February 1, 2014 Anbil et al.	Managed Markets: Positioning Your Product For Success with Pull Through Strategies A patient-centric approach to drug development delivers the benefits that actually create value
Pharmaceutical Executive June 1, 2005 Boschwitz et al.	Track Patients, Not Prescriptions Why pharma companies reject anonymous patient-level data, and why they can't do without it for long.
Pharmaceutical Executive October 1, 2011	Arming up for the Digital Revolution As a longtime advocate of new approaches to meeting customer needs in pharma, Martin Wygod sees the biggest change as the coming growth of digital platforms as the principal source of information and communication in healthcare.
Bio-IT World June 2006 Michael A. Greeley	Backwards Influence Biotech companies must think downstream as they consider what drugs to develop. Many companies are introducing cost-effectiveness analysis earlier in the discovery process.
Pharmaceutical Executive June 9, 2014 Kleinrock & Noor	Pharm Exec's Pharma 50 2014 For those companies in this year's Pharm Exec Top 50, meeting the accelerating market demand for specialty products has become an acute strategic imperative.
Managed Care February 2002 Ira Studin	Reframing the Pharmaceutical Manufacturer/Health Plan Relationship in Managed Care It is suggested that health plans address "total cost-of-care savings" in their budget process, and the pharmaceutical manufacturers establish a "consultative service function" in their managed care divisions...
Pharmaceutical Executive January 1, 2011	The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade.
Pharmaceutical Executive March 3, 2014 Mason Tenaglia	The New Metrics of Market Success Profitability now depends on metrics to help companies answer a key strategic question: "stay the course" with more investment in sales and marketing? Or "stand down" and deploy those scarce assets somewhere else?
Bio-IT World September 16, 2004 Michael A. Greeley	Platforms for Pathways Investor interest in the next great blockbuster drug has been blistering hot; Phase II and Phase III compound companies are being funded at a near record-breaking pace now that the IPO window seems to be slightly open
Pharmaceutical Executive July 1, 2012 William Looney	The Learning Curve In a wake up call to this year's Emerging Leaders a group of St. Joseph's Business School Health Management alumni say time has no limit on surprises; change for pharma is here and it's good.
Bio-IT World Dec 2005/Jan 2006 Michael A. Greeley	Infinite Demand for the Unavailable The bio-IT field is once again attracting venture capital, but at a more moderate, deliberate pace than the euphoria of the late 1990s.
Pharmaceutical Executive December 1, 2010 Zhu Shen	China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda
Pharmaceutical Executive August 1, 2011 Jennifer Ringler	The Adherence Fight: A TKO? Why does the match against medicines compliance always seem to end in an easy knockout?
Bio-IT World July 2005 Michael A. Greeley	CEO Lessons on Product and Market In the face of extraordinary R&D budgets generated by biopharma industries, bio-IT companies must refine their value propositions in the hopes that meaningful (predictable and repeatable) revenue streams can be created.
Pharmaceutical Executive December 1, 2011 William Looney	The Medicines Adherence Challenge Keeping skittish patients on their medicines ought to be a strategic priority for Big Pharma, but is it? An expert round table examines how best to make progress and agree on some practical steps for incorporation in the campaign agenda.
Bio-IT World October 10, 2003	Funds Up Venture financing numbers are in for Q2, and the news is not all bad.
Pharmaceutical Executive May 1, 2006 Stephen Wray	Alternative Media: Interactive=Integration Interactive technology allows marketers to keep up with the demands of both physicians and consumers.
Pharmaceutical Executive February 1, 2012 Sarah Krug	Introducing the 'Chief Patient Officer' Now is the time for pharma companies to appoint a Chief Patient Officer, a new position designed to build an accord around patient trust.
Bio-IT World July 15, 2003 Michael Greeley	Finally, the Bottom Has pharma bought all the solutions it needs? The flood of genomic data indicates no.
Pharmaceutical Executive March 1, 2011 William Looney	Making Sense of Market Chaos Pharma can be an insular industry, with limited capacity to gaze beyond its own narrow frame of vision
Pharmaceutical Executive November 1, 2011 Bill Drummy	Pharma's Visit to the Plastic Surgeon The bigger the company, the thicker the sclerosis, the more they need to suck out the fat.
Pharmaceutical Executive August 1, 2008 George Koroneos	Hard of (Ad)hering Companies have responded to declining profits with a proliferation of patient compliance programs. But where is pharma in this paradigm shift?
Pharmaceutical Executive April 1, 2014 William Looney	The Trials of Commerce Four commercial line executives serve as our jury of peers on what's in store for the future of pharma, and discuss the changing criteria for market success, from drugs to consumer products to vaccines.
Bio-IT World March 8, 2005 John Russell	Entelos' Lofty Aspirations This is an interesting period for systems biology's wing of predictive biology companies. The label's luster is fading, but buoyed by pharma's growing interest, they are trying to figure out how to grow.
Pharmaceutical Executive May 1, 2009 Lee Slovitt	A Day Late and a Dollar Short Pharma marketers face a crisis in digital media. But there's a way to turn it around.
Pharmaceutical Executive January 1, 2007 Jeffrey Zornitsky	Sales Management: Get Committed By better managing relationships with physicians, pharma companies can develop a base of dedicated prescribers.
Pharmaceutical Executive February 1, 2006 Chandler & Chicco	Public Relations: Damage Control Unless pharma defines a compelling story, and defends it vigorously in the consumer marketplace, others will enter that vacuum and tell the story for it -- in far less flattering ways
Pharmaceutical Executive September 1, 2013 William Looney	High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets.
Pharmaceutical Executive May 1, 2012 William Looney	Information Overload Data has become as important as the drug in driving success in healthcare.
Bio-IT World October 14, 2004 Michael Greeley	Go East Business is great in China, and the government is strongly encouraging the local biotech industry.
The Motley Fool December 21, 2004 Charly Travers	Invest With Fewer Side Effects Averse to risk? Check out these nontraditional drug companies: Biogen Idec... Elan... Salix Pharmaceuticals... Atrix Laboratories... etc.
Bio-IT World April 15, 2003 Michael Greeley	Bio Battles Upstream As biotech business models evolve, the question remains: Which will survive?
Bio-IT World December 15, 2003 Michael Greeley	Tiny Devices, Big Opportunities Parallel advances in drug formulation and microprocessing and other manufacturing technologies are creating new products and services as these industries start to intersect.
Pharmaceutical Executive August 1, 2013 Joseph Saba	New Rules for a New Africa Declining revenue growth in the United States and Europe have sent pharmaceutical companies in search of opportunities in the BRICs and other emerging economies. Now, companies are finally turning their attention to Africa.
Pharmaceutical Executive January 1, 2012 William Looney	Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.
Pharmaceutical Executive October 1, 2010	When the Payer IS the Player As Medicare, Medicaid, and the nation's web of private payers gain market power, how can pharma stay ahead of the cost-containment curve?
Pharmaceutical Executive September 1, 2012 Al Topin	Doctors' Words No Longer Gospel In the digital age, physicians don't call the shots when it comes to healthcare guidance. Marketers must appeal to multiple sources in seeking ways to garner patient adherence and loyalty.
CRM August 1, 2009 Lauren McKay	The New Prescription for Pharma To address trends in the industry, pharmaceutical companies must do more with less and reshape their messages - not the easiest of tasks.
Pharmaceutical Executive May 1, 2012	Super-Size Me Finding opportunities in the information explosion: big data, big challenges and big rewards.
Pharmaceutical Executive May 1, 2009	Ad(Ventures) in Pharmaland Despite the downside in ad spend, an upside remains in the digital space that's wide open for exploration.
Pharmaceutical Executive January 1, 2011 Walter Armstrong	The List It's a new year. Even pharma, with its glacial timelines, has its "Out with the old, in with the new" moment. Welcome to 2011!
Pharmaceutical Executive October 1, 2005 Mark J. Ahn	It's All Academic: Biotechs Looking to Universities Pharmaceuticals and academic institutions are forming alliances at an increasing rate to exploit the promise of emerging biological insights.
Pharmaceutical Executive January 1, 2012 Elys Roberts & Sarah Phillips	The Emergence of the Pro-Patient How can pharma embrace and interact with increasingly informed and demanding patients to bring positive outcomes for all?
Pharmaceutical Executive January 1, 2009 Walter Armstrong	Up in the Air If pharma execs start upping their consumption of antihypertensives and anxiolytics (all branded, of course) in the months to come, it won't be a huge surprise. The industry faces a truly unprecedented number of political and policy challenges.
Pharmaceutical Executive March 1, 2007 Jeffrey Zornitsky	Sales Management: Get Committed By better managing relationships with physicians, pharma companies can develop a base of dedicated prescribers.
Pharmaceutical Executive August 1, 2011 Bill Drummy	The Slow Dance Toward Obsolescence Does Big Pharma have the emotional connection and intellectual commitment to move with the pace of change?
Pharmaceutical Executive August 1, 2011 Peter Houston	Google+ and Pharma Is Google+ the social media platform that pharma has been waiting for?
Pharmaceutical Executive September 1, 2011	Turning the Ins and Outs of Marketing Inside-Out Keeping your finger on the pulse of consumers leads to better, more actionable insights and better results.